EN DE

Ping An Healthcare and Technology Company Ltd (1833) Fair Value & Analysis

Healthcare · HK · Market cap HK$15.0B

PA Ping An Healthcare and Technology Company Ltd 1833 · HK
PriceHK$7.47
Fair ValueHK$3.33
Upside-55.4%
Quality55/100
Watch Ping An Healthcare and Technology Company Ltd for free, get notified when fair value or trend changes. Watch for free
Weak Growth
Thin margins · 6.9% net margin
Low debt · generates free cash flow
Mixed vs. peers (7/14)
Narrow moat 28/100
Evidence: High Range HK$2.51 – HK$3.33 Share as image

Fair value as of: Aug 13, 2026

From 26 valuation models · updated 3 days ago

Share price +0.2% over the past month.

A solid business, but screening 55% overvalued on our models.

What matters now

  • The price sits above even our optimistic bull case (HK$3.33). The favourable scenario is already priced in.
  • Solid but not exceptional quality (55/100) and above fair value, neither a clear bargain nor a standout compounder.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

HK$103.30 HK$6.04 Fair Value HK$3.33 Mar 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range HK$6.04 – HK$103.30 · fair‑value band HK$2.51 – HK$3.33 · the HK$7.47 price screens above the HK$3.33 fair value. Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Ping An Healthcare and Technology Company Ltd (1833) currently trades at HK$7.47, while our model-based Fair Value estimate is HK$3.33, implying the stock looks roughly 55.4% overvalued today. The Quality Score stands at 55/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, Ping An Healthcare and Technology Company Ltd generated revenue of HK$5.5B at a net margin of 6.9%. Revenue grew 9.3% year over year. It earns a return on equity of 5.6%. The balance sheet holds a net cash position of HK$2.4B. Fundamentals as of Aug 13, 2026

Our scenario range runs from HK$2.51 (bear case) to HK$3.33 (bull case); at HK$7.47, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat. The share trades about 69% below its 52-week high and 14% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -64% fair-value upside, at -55%, 1833 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF HK$3.53 HK$5.42 HK$8.67 80
Residual Income HK$3.50 HK$3.50 HK$3.18 76
Rev-Margin DCF HK$2.17 HK$2.66 HK$3.30 74
All 26 models by family
DCF Models
FCF DCF HK$3.55 HK$5.65 HK$9.37 38
Owner Earnings HK$3.69 HK$5.89 HK$9.82 31
5Y Revenue Exit HK$2.17 HK$2.64 HK$3.22 39
5Y EBITDA Exit HK$2.42 HK$3.16 HK$4.06 41
5Y P/E Exit HK$3.76 HK$5.97 HK$8.53 38
10Y Revenue Exit HK$2.60 HK$3.20 HK$4.04 36
10Y EBITDA Exit HK$2.78 HK$3.59 HK$4.76 37
10Y P/E Exit HK$3.67 HK$5.67 HK$8.57 35
Earnings-Based
Graham-Dodd HK$1.21 HK$5.96 HK$8.22 54
Lynch FV HK$1.60 HK$2.29 HK$2.98 50
PEG = 1.0 HK$1.60 HK$2.29 HK$2.98 46
EPV HK$1.52 HK$1.58 HK$1.64 59
Dividend Discount
Gordon GGM HK$16.43 HK$34.16 HK$54.19 70
DDM Multi-Stage HK$16.43 HK$28.81 HK$35.85 61
Multiples
P/E Multiple HK$2.94 HK$3.93 HK$4.91 63
P/S Multiple HK$2.28 HK$3.03 HK$3.79 58
P/B Multiple HK$2.28 HK$3.03 HK$3.79 55
EV/EBIT HK$1.71 HK$1.90 HK$2.10 53
EV/EBITDA HK$1.96 HK$2.24 HK$2.52 54
EV/Revenue HK$1.54 HK$1.72 HK$1.90 43
Asset-Based
NCAV (Graham) HK$2.33 HK$3.13 HK$4.66 50
Growth DCF
Growth DCF HK$3.53 HK$5.42 HK$8.67 80
Rev-Margin DCF HK$2.17 HK$2.66 HK$3.30 74
Economic Profit
Residual Income HK$3.50 HK$3.50 HK$3.18 76
ROIC Compounder HK$1.52 HK$1.58 HK$1.64 72
Growth Earnings
Growth-Adj P/E HK$2.54 HK$3.62 HK$4.71 68

Widest divergence: Dividend Discount (HK$28.81) versus Economic Profit (HK$1.58). Highest evidence: Growth DCF (80).

Notify me when 1833 reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) HK$5.5B
Revenue growth (YoY) +9.3%
Net margin 6.9%
Return on equity 5.6%
Free cash flow HK$392M FY2025
P/E ratio 33.7 as of Jul 2, 2026
More key figures
Operating margin 4.9%
EPS (TTM) HK$0.0700
EPS growth (YoY) +378%
Net cash HK$2.4B FY2025

Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 55/100

Of which business quality 56 · Market factors (momentum, volatility) 14

Profitability 28
Margins and returns on capital today
Quality Growth 69
Are margins and returns improving?
Cashflow 53
Earnings quality: real cash, not paper profit
Fin. Strength 91
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 36
Calm price path (market factor)
Momentum 5
Price trend over the last 3–12 months (market factor)
52W Momentum 3
Distance to the 52-week high (market factor)
Net Issuance 0
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Ping An Healthcare and Technology Company Limited, together with its subsidiaries, operates an online healthcare services platform in China.

Full company description

Ping An Healthcare and Technology Company Limited, together with its subsidiaries, operates an online healthcare services platform in China. It offers online diagnosis and treatment, online consultation services, audio and video consultations, standardized healthcare service packages, health check-ups, genetic testing, concierge services, health management services, smart device sales, and consulting services. The company also provides online consultation, hospital referral and appointment, inpatient arrangement, and second opinion services; prepaid cards and health check-up services. The company online consultation, hospital referral, inpatient arrangement, second opinion services, electronic prescriptions, health management, prepaid packages for healthcare products and services, provision of products in the Group's health mall, advertising services, and consulting services, as well as operates an insurance agency. In addition it is involved in the integrated finance business. The company was incorporated in 2014 and is headquartered in Shanghai, China. Ping An Healthcare and Technology Company Limited operates as a subsidiary of Glorious Peace Limited.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Ping An Healthcare and Technology Company Ltd reported revenue of HK$5.5B in FY2025 versus HK$7.3B in FY2021, a compound −7.1%/yr. Reported net income was HK$380M in FY2025.

Growth Quality 40/100
Revenue growth is weak, negative or inconsistent.
Latest Revenue (FY 2025)
HK$5.5B
Latest YoY
+13.7%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−4.1%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−4.5%
Avg. growth/yr (10Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+34.7%
Revenue −7.1%/yr
FY21 HK$7.3B
FY22 HK$6.2B
FY23 HK$4.7B
FY24 HK$4.8B
FY25 HK$5.5B
Net income
FY21 −HK$1.5B
FY22 −HK$636M
FY23 −HK$323M
FY24 HK$81.4M
FY25 HK$380M

1833 screens 55% overvalued. Compare with Veeva Systems Inc →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Ping An Healthcare and Technology Company Ltd Fair Value". https://www.fairvalue-calculator.com/stock/1833

Peer Group

Health Information Services · 125 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 55 · Below median
Fair Value upside −55% · Below median
Return on equity (TTM) 6% · Above median
Return on assets 1% · Below median
Net margin (TTM) 7% · Above median
Operating margin (TTM) 5% · Above median
Revenue growth 9% · Above median
Debt / equity 0.00× · Lower than median

Valuation Multiples vs Health Information Services median · lower = cheaper

P/E (TTM) 33.7× · Pricier than median
P/B 1.52× · Cheaper than median
P/S (TTM) 2.75× · Pricier than median
P/FCF 4.9× · Cheaper than median
EV/EBITDA 53.0× · Pricier than 75% of peers
PEG 3.05× · Pricier than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0 · sector 0
FUTURE 47 · sector 29
PAST 22 · sector 7
HEALTH 100 · sector 98
DIVIDEND 0 · sector 42

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Stock Price Fair Value vs Fair Value
Veeva Systems Inc VEEV $241.51 $91.49 -62%
Pro Medicus Limited PME A$183.71 A$23.74 -87%
BrightSpring Health Services, Inc BTSG $59.68 $21.31 -64%
HealthEquity, Inc HQY $105.50 $56.63 -46%
Hinge Health, Inc HNGE $86.32 $24.03 -72%
10x Genomics, Inc TXG $58.48 $17.18 -71%
Waystar Holding WAY $24.54 $12.86 -48%
XtalPi Holdings 2228 HK$8.19 HK$1.04 -87%
Doximity, Inc DOCS $24.99 $25.91 +4%
Privia Health Group PRVA $21.54 $5.26 -76%

Compare Ping An Healthcare and Technology Company Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Ping An Healthcare and Technology Company Ltd (1833) overvalued or undervalued?
As of Aug 13, 2026, our model estimates a fair value of HK$3.33 versus a price of HK$7.47, about −55% (overvalued).
What is the fair value of 1833?
Our model-based fair value for Ping An Healthcare and Technology Company Ltd is HK$3.33 (as of Aug 13, 2026), built from audited fundamentals. The current price is HK$7.47.
What is the quality score of 1833?
Ping An Healthcare and Technology Company Ltd has a Quality Score of 55/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Ping An Healthcare and Technology Company Ltd (1833)?
Ping An Healthcare and Technology Company Ltd reported trailing-twelve-month revenue of about HK$5.5B (latest available figure, as of Aug 13, 2026).
What is the net profit margin of 1833?
The net profit margin of Ping An Healthcare and Technology Company Ltd is about 6.9%, meaning it keeps roughly 6.9% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Ping An Healthcare and Technology Company Ltd and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.